Difelikefalin, sold under the brand name Korsuva, is an analgesic opioid peptide used for the treatment of moderate to severe itching. It acts as a peripherally specific, highly selective agonist of the \u03ba-opioid receptor (KOR). Difelikefalin was approved for medical use in the United States in August 2021. The U.S. Food and Drug Administration considers it to be a first-in-class medication<\/p>\n
KORSUVA is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD).<\/p>\n
If difelikefalin injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Note:<\/strong> KORSUVA is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA (difelikefalin) is a kappa opioid receptor agonist. Difelikefalin is a synthetic peptide with a single stereoisomer and is present as an acetate salt.<\/p>\n Approval Date: 2021 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import difelikefalin injection\u201d based on the information you provide.<\/p>\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.<\/p>\nReferences<\/h3>\n
\n
\nSee Drugs@FDA for information about all of CDER\u2019s approved drugs and biological products.<\/a><\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"KORSUVA (difelikefalin) injection,
\nfor intravenous use Initial U.S. Approval: 2021<\/h2>\nFacts about difelikefalin Injection<\/h4>\n
\nProprietary Name: On Request
\nActive Ingredient(s): pruritus associated with chronic kidney disease (CKD-aP)
\nDosage Forms And Strengths: Injection: 65 mcg \/1.3 mL (50 mcg\/mL) of difelikefalin.
\n<\/strong>International non-proprietary name (INN) or common name: difelikefalin injection
\nTherapeutic area (MeSH): moderate to severe itching
\nMarketing: Vifor (International) Inc.
\nEMA Approved: 2021
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a><\/p>\nAccess the best support services globally<\/h4>\n